| 000 | 01756 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515002421.0 | ||
| 264 | 0 | _c20051214 | |
| 008 | 200512s 0 0 eng d | ||
| 022 | _a1538-7933 | ||
| 024 | 7 |
_a10.1111/j.1538-7836.2005.01435.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoudemand, J | |
| 245 | 0 | 0 |
_aPharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. _h[electronic resource] |
| 260 |
_bJournal of thrombosis and haemostasis : JTH _cOct 2005 |
||
| 300 |
_a2219-27 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Coagulation Tests |
| 650 | 0 | 4 | _aConsumer Product Safety |
| 650 | 0 | 4 |
_aFactor VIII _xbiosynthesis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPharmacokinetics |
| 650 | 0 | 4 |
_aSterilization _xmethods |
| 650 | 0 | 4 | _aVirus Inactivation |
| 650 | 0 | 4 |
_avon Willebrand Diseases _xdrug therapy |
| 650 | 0 | 4 |
_avon Willebrand Factor _xadministration & dosage |
| 700 | 1 | _aScharrer, I | |
| 700 | 1 | _aBerntorp, E | |
| 700 | 1 | _aLee, C A | |
| 700 | 1 | _aBorel-Derlon, A | |
| 700 | 1 | _aStieltjes, N | |
| 700 | 1 | _aCaron, C | |
| 700 | 1 | _aScherrmann, J M | |
| 700 | 1 | _aBridey, F | |
| 700 | 1 | _aTellier, Z | |
| 700 | 1 | _aFederici, A B | |
| 700 | 1 | _aMannucci, P M | |
| 773 | 0 |
_tJournal of thrombosis and haemostasis : JTH _gvol. 3 _gno. 10 _gp. 2219-27 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1538-7836.2005.01435.x _zAvailable from publisher's website |
| 999 |
_c15824831 _d15824831 |
||